A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials

Plain-language summary

This study aims to identify people who may have primary ciliary dyskinesia (PCD) using a genetic testing kit and connect them with potential clinical trials. It enrolls people aged 18 and older who have a PCD diagnosis or are deemed eligible through a screening questionnaire. It is a study without a designated phase and is currently active but not recruiting new participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

ReCode Therapeutics

Intervention

Sano Genetics Testing Kit

Start date

8/31/2023

Estimated completion

12/1/2025

Countries

United States

Related genes

Locations

• Menlo Park, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Participant must be at least 18 years old.
2. Participant must have a prior diagnosis of PCD or be deemed eligible upon completion of the PCD-enrichment screening questionnaire.
3. Participant must be under the care of an HCP for their PCD or symptoms potentially related to PCD.
4. Participant must be able to read, write, and understand English, and reside in a country where the shipment of biological samples is allowed.
5. Participant must be willing to be tested for genes involved in PCD.
6. Participant must be willing to be notified of eligibility for clinical studies (if appropriate)

Exclusion Criteria:

In ability to meet any of the inclusion criteria